Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graft-vs-host disease: a critical effector role for interleukin-1. Transplant Proc 1993;25(1 Pt 2):1216–1217.
Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 2020;382(19):1811–1822. DOI: 10.1056/NEJMoa1911326.
Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio 2015;6(3):e00638-15. DOI: 10.1128/mBio.00638-15.
Gralinski LE, Menachery VD, Morgan AP, et al. Allelic variation in the toll-like receptor adaptor protein Ticam2 contributes to SARS-coronavirus pathogenesis in mice. G3 (Bethesda) 2017;7(6):1653–1663. DOI: 10.1534/g3.117.041434.
Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 2008;4(12):e1000240. DOI: 10.1371/journal.ppat.1000240.
Debaugnies F, Mahadeb B, Ferster A, et al. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol 2016;145(6):862–870. DOI: 10.1093/ajcp/aqw076.
Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020;53:25–32. DOI: 10.1016/j.cytogfr.2020.05.003.
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol 2020. DOI: 10.1002/jmv.25948.
Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814–818. DOI: 10.1002/jmv.25801.
